A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

BACKGROUND: Sasanlimab is an antibody to the programmed cell death protein 1 receptor. We report updated data of subcutaneous sasanlimab in non-small-cell lung cancer (NSCLC) and urothelial carcinoma dose expansion cohorts from a first-in-human phase Ib/II study. PATIENTS AND METHODS: Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, B.C., Penkov, K., Bondarenko, I., Kurochkin, A., Pikiel, J., Ahn, H.K., Korożan, M.E., Osipov, M., Odintsova, S., Braiteh, F., Ribas, A., Grilley-Olson, J.E., Lugowska, I., Bonato, V., Damore, M.A., Yang, W., Jacobs, I.A., Bowers, M., Li, M., Johnson, M.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485400/
https://www.ncbi.nlm.nih.gov/pubmed/37385154
http://dx.doi.org/10.1016/j.esmoop.2023.101589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485400/
https://www.ncbi.nlm.nih.gov/pubmed/37385154
http://dx.doi.org/10.1016/j.esmoop.2023.101589

Ejemplares similares